Related Experiment Video
Updated: Jul 17, 2026
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
Antitumor effects of ZD6474 on head and neck squamous cell carcinoma
Daisuke Sano1, Mariko Kawakami, Kyoko Fujita
1Department of Biology and Function in the Head and Neck, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan. t046028d@yokohama-cu.ac.jp
Abstract:
Angiogenesis is required for tumor growth and metastasis and, therefore, represents a target for cancer treatment. While many factors have been implicated in promoting angiogenesis, vascular endothelial growth factor (VEGF) plays a key role in tumor angiogenesis. ZD6474 is a potent VEGF receptor-2 (VEGFR-2) tyrosine kinase inhibitor which also has activity against the epidermal growth factor receptor (EGFR) tyrosine kinase. The purpose of this study was to investigate the sensitivity of head and neck squamous cell carcinoma (HNSCC) cell lines to ZD6474, and to evaluate its antitumor efficacy on HNSCC xenografts. This is the first demonstration of antitumor effects of ZD6474 on HNSCC. In vitro ZD6474 displayed antiproliferative effects on HNSCC cells and inhibition of VEGFR-2 and EGFR pathways. In vivo ZD6474 displayed antitumor activity, induced apoptosis and antiangiogenic activity on nude mice bearing an established xenograft of YCU-H891 cells. These results suggest that ZD6474 has the potential to inhibit two key pathways in tumor growth via inhibition of VEGF-dependent tumor angiogenesis and via inhibition of EGFR-dependent tumor cell proliferation.
Insights
ZD6474, a dual inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2) and epidermal growth factor receptor (EGFR) tyrosine kinases, shows significant antitumor effects in head and neck squamous cell carcinoma (HNSCC). This study demonstrates ZD6474
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Tumor growth and metastasis depend on angiogenesis, a process significantly driven by vascular endothelial growth factor (VEGF).
- VEGF receptor-2 (VEGFR-2) and epidermal growth factor receptor (EGFR) pathways are crucial targets in cancer therapy.
- Head and neck squamous cell carcinoma (HNSCC) requires angiogenesis for progression.
Purpose of the Study:
- To investigate the sensitivity of HNSCC cell lines to ZD6474, a dual VEGFR-2 and EGFR tyrosine kinase inhibitor.
- To evaluate the antitumor efficacy of ZD6474 in HNSCC xenograft models.
- To establish the potential of ZD6474 in targeting key pathways in HNSCC.
Main Methods:
- In vitro assessment of ZD6474's antiproliferative effects on HNSCC cell lines.
- Inhibition analysis of VEGFR-2 and EGFR pathways in HNSCC cells treated with ZD6474.
- In vivo evaluation of ZD6474's antitumor activity, apoptosis induction, and antiangiogenic effects in HNSCC xenografts in nude mice.
Main Results:
- ZD6474 exhibited antiproliferative effects on HNSCC cells in vitro.
- Inhibition of both VEGFR-2 and EGFR signaling pathways was observed in vitro.
- In vivo studies showed that ZD6474 possesses antitumor activity, induces apoptosis, and exerts antiangiogenic effects in HNSCC xenografts.
Conclusions:
- ZD6474 demonstrates significant antitumor potential against HNSCC.
- The drug effectively inhibits both VEGF-dependent tumor angiogenesis and EGFR-dependent tumor cell proliferation.
- ZD6474 represents a promising therapeutic agent for targeting HNSCC by simultaneously inhibiting two critical tumor growth pathways.
